New Indication: Nivolumab in Esophageal SCC

Global, randomized, open-label, phase 3 trial (CheckMate 648)

Unresectable advanced, recurrent, or metastatic esophageal squamous-cell carcinoma with no previous systemic therapy for advanced disease

Nivolumab plus chemotherapy (n=321) or nivolumab plus ipilimumab (n=325) or chemotherapy alone (n=324)

mOS: 15.4 vs. 9.1 mos; (HR:0.54; P<0.001) for nivolumab plus chemotherapy vs chemotherapy (PD-L1 >=1 group)

mOS: 13.7 vs 9.1 mos; (HR:0.64 p=0.001) for nivolumab plus ipilimumab vs chemotherapy (PD-L1 >=1 group)

Grade 3 AE >= 47% vs 32% vs 36%

Discontinuation of any drug: 34% vs 18% vs 19%

Treatment-related serious adverse event 24% vs 32% vs 16%

Reviewed by Hasan Cagri Yildirim, MD on May 20, 2022

nivolumab